Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Chemotherapy

Background:

• Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
• Relapse of ALL presents significant treatment challenges.
• Effective salvage therapies for pediatric ALL relapse are crucial.

Purpose of the Study:

• To evaluate the efficacy of an intensive induction, consolidation, and maintenance chemotherapy regimen for children with early first bone marrow relapse of ALL.
• To assess event-free survival (EFS) and overall survival rates in this patient cohort.

Main Methods:

• Twenty-seven evaluable children with early first bone marrow relapse of ALL received a 35-day induction regimen (daunomycin, vincristine, prednisone, teniposide, cytosine arabinoside, L-asparaginase) followed by maintenance therapy.
• Intrathecal chemotherapy (methotrexate, hydrocortisone, Ara-C) was administered during induction/consolidation.
• Patients were monitored for remission status and survival outcomes.

Main Results:

• Twenty-three of 27 patients (85%) achieved remission by the end of induction/consolidation.
• Event-free survival (EFS) was 0.64 at 12 months for M1 patients at day 35, decreasing to 0.32 by 30-48 months.
• A subgroup with M3 status at day 35 but M1 at day 56 had poor EFS, with all relapsing by 15 months.
• Less than 20% of patients are expected to be alive after 5 years.

Conclusions:

• The intensive chemotherapy regimen achieved high initial remission rates in children with relapsed ALL.
• Long-term event-free survival and overall survival remain limited, highlighting the need for novel therapeutic strategies.
• Prognosis is poor for patients with persistent minimal residual disease (M3) after initial induction therapy.